Multimodality magnetic resonance imaging study of Huangjingjiannao prescription in the treatment of vascular mild cognitive impairment

Early Phase 1

Recruiting

• Conditions: F06.700; Vascular Mild Cognitive Impairment

• Registration Number: ITMCTR2022000016
• Lead Sponsor: Guang'anmen Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 November 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

(1) Between 40 and 75 years old; (2) Primary school degree or above or the same educational level, with a certain degree of Education: (3) have impairment symptoms in any cognitive field; (4) The overall cognitive function was basically normal, and the MMSE score was less than 24; (5) The ability of daily living was basically normal, and the score of ADL ranged from 20 to 26; (6) Not in accordance with the diagnosis of dementia, clinical dementia rating scale (CDR) =0.5; (7) TCM syndrome belongs to kidney deficiency and blood stasis syndrome, TCM syndrome score = 7 points; (8) Brain CT or MRI has the imaging manifestations of ischemic leukoencephalopathy. Cranial CT: localized in paraventricular area or bilateral patchy or diffuse low-density area extending to the center of semi oval (CT value is 5-10hu lower than the normal value), the boundary is fuzzy, and the enhanced scan is not enhanced. Cranial MRI showed T2 high signal and T1 signal or low signal changes in paraventricular and deep white matter areas; (9) The patient has independent ability, can cooperate with the test plan, and voluntarily sign the informed consent after being informed.

Exclusion Criteria

(1) Accompanied by macrovascular cerebral infarction, extensive or critical cerebral infarction, and cerebral hemorrhage at critical sites. (2) Patients with a history of using intellectual stimulants, cholinesterase inhibitors, ergot alkaloids, calcium antagonists, Ginkgo biloba extract and other drugs in the past six months; Have serious sleep disorders or other mental diseases, and have a history of drug or alcohol dependence and abuse; (3) Other diseases that may cause cognitive impairment, such as thyroid dysfunction, severe anemia (including significant vitamin B12 or folic acid deficiency), infection, syphilis, HIV, etc; (4) Patients with severe heart, liver and kidney dysfunction; Patients who are not suitable to participate in the drug test, such as patients with other serious heart, liver and kidney function damage, serious heart and cerebrovascular diseases, uncontrolled hypertension, hyperglycemia and arrhythmia; (5) Serious visual and hearing impairment, unable to cooperate with the examination (6) patients who are allergic to the test drug or have high sensitivity constitution; (7) Pregnant and lactating women (8) without informed consent

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Symptom score scale of Chinese medicine;MoCA;Neuropsychological scale test;ADL;HAMD-17;MMSE;

Secondary Outcome Measures

Name	Time	Method
Blood sugar;TG;low density lipoprotein(LDL);D-dimer;high density lipoprotein(HDL);prothrombin time(PT);Blood calcium;prothrombin time(PT);Fibrinogen(FIB);activated partial thromboplastin time(APTT);HCY;TC;